Roivant CEO Matt Gline at #BIO24 (Brian Benton Photography)
September 18, 2024 10:57 AM EDT
Deals

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

Max Bayer

Pharma Reporter

Roivant is once again reap­ing the ben­e­fits of its be­spoke busi­ness mod­el. This time, it’s sell­ing Der­ma­vant to Organon for up to $1.2 bil­lion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Il­lu­mi­na's pitch for new ma­chines: You, too, can se­quence DNA

A service from the Financial Times